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Abstract: Pegylated liposomal doxorubicin (PLD) has become a major component in the 
routine management of epithelial ovarian cancer. The drug is frequently employed as a single 
agent in the platinum-resistant setting, and recently reported data reveal the superiority of the 
combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delay-
ing the time to disease progression in women with recurrent (potentially platinum-sensitive) 
disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel 
targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant 
population, compared with the sequential administration of single agents active in this setting, 
remains to be determined.
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Standard management of epithelial ovarian cancer
Initial management of epithelial ovarian cancer includes surgical staging and an attempt 
at optimal and, if possible, complete surgical cytoreduction.1
Surgery is followed by delivery of platinum-based chemotherapy, which in the 
setting of small volume residual disease may include the delivery of at least the 
platinum agent via the intraperitoneal route.1,2 Multiple trials conducted over the past 
decade have failed to document the superiority of a variety of approaches compared 
with the standard doublet of a platinum (carboplatin or cisplatin) agent plus a taxane 
(paclitaxel or docetaxel).3
An important Phase 3 trial conducted by the Japanese Gynecologic Oncology Group 
revealed the striking improvement in progression-free survival (PFS) associated with 
the weekly administration of paclitaxel compared with the standard every-3-week 
regimen, with an improvement in 3-year overall survival.4 Data regarding median 
overall survival are likely to be reported within the next year.
Two preliminary reports of Phase 3 trials that compared a carboplatin plus pacli-
taxel regimen to this two-drug program plus the addition of the anti-angiogenic agent, 
bevacizumab, revealed the novel program significantly improved PFS.5,6 Data on 
overall survival are pending.
An alternative approach to initial treatment of advanced ovarian cancer in the 
setting where the presence of extensive disease would appear to prevent successful 
initial surgical cytoreduction would be to deliver several cycles (generally 3 or 4) 
of platinum/taxane chemotherapy (after obtaining histological documentation of a 
malignancy consistent with an ovarian or primary peritoneal cancer) and to follow Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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this with an attempt at resection of all macroscopic residual 
cancer. Recently reported Phase 3 trial data support this 
approach (neoadjuvant chemotherapy) to disease manage-
ment in appropriately selected patients.7
In individuals who achieve a clinically defined complete 
response (normalization of serum CA-125 antigen level, nor-
mal CT [computed tomography] scan of the abdomen/pelvis, 
normal physical examination, no symptoms suggestive of 
persistent cancer), treatment is generally discontinued after 
the 6–8 platinum-based treatment cycles. One evidence-based 
trial revealed that the continuation of single agent monthly 
paclitaxel for a period of 12 months significantly delays the 
time to subsequent disease progression,8 but to date, there 
remains no evidence that this strategy (or any other main-
tenance approach) improves overall survival in epithelial 
ovarian cancer.
Unfortunately, despite the fact the majority of advanced 
ovarian cancer patients (70%–80%) respond to platinum-
based chemotherapy, ultimate recurrence of the disease is 
the rule, rather than the exception.1 A variety of management 
approaches may be utilized in this setting, with platinum-
based treatment programs generally initially employed in 
women whose disease has remained in remission for at 
least 6 months (so-called, “platinum-sensitive recurrence”), 
although many in the gynecologic cancer research com-
munity believe it is only after a “platinum-free interval” of 
at least 12 months that it should be considered essentially 
required (“standard-of-care”) to initially re-treat with a 
platinum-based program.
It is relevant to note here that there is no current evidence 
that any treatment regimen delivered to ovarian cancer 
patients whose disease had recurred following an initial 
response, or where the malignancy is documented to persist 
following the completion of 6–8 cycles of platinum-based 
primary chemotherapy, has the legitimate potential to cure the 
cancer, even if it is possible that survival may be prolonged 
with therapy known to be biologically and clinically active 
in this setting. Therefore, it is essential to appreciate that 
treatment in the “second-line” (and beyond) setting must be 
considered to be administered to improve disease-related 
symptoms, delay the time until the development of such 
symptoms, help optimize the patient’s overall quality-of-
life, and prolong overall survival, but not to permanently 
eliminate the malignancy.
In patients whose ovarian cancer recurs early, or where 
it is subsequently documented that the cancer is platinum 
resistant, a number of single agent anti-neoplastic drugs 
have been documented to produce objective response rates 
in more than 10% of the treated population (Table 1).9 
  Importantly, there is no current evidence-based Phase 3 trial 
data that any combination chemotherapy regimen is superior 
to single-agent treatment in platinum-resistant (platinum-
free   interval ,6 months) ovarian cancer, nor that any one 
of multiple possible single agents that may be employed in 
this setting is therapeutically superior to alternative   strategies. 
It should be noted, however, that the toxicity profiles of 
the individual agents that may be employed in this clinical 
circumstance vary substantially.
In general, the choice of treatment in the platinum-
resistant setting is made based on the previous toxicity 
experienced by the patient (eg, persistent neuropathy from 
prior platinum/taxane), the actual availability of, and payment 
for (eg, government, third-party private insurance) specific 
treatment options, and individual choice. Further, where 
available, treatment on a clinical trial may be a reasonable 
therapeutic option.
Currently, an individual ovarian cancer patient may 
  ultimately receive as few as several and as many as a dozen 
treatment regimens during the natural history of her cancer. 
It is relevant to note here that the duration of survival follow-
ing initial documentation of disease progression in ovarian 
cancer is increasingly likely to actually exceed the time 
period from diagnosis to the first evidence of recurrence.
Further, with the increased effectiveness of anti-
  neoplastic therapy in epithelial ovarian cancer, a substantial 
  percentage of women presenting with advanced disease 
will be anticipated to survive for more than 5 years follow-
ing initial diagnosis. As a result, it is not unreasonable to 
characterize this clinical scenario in many patients as being 
a very serious but also legitimate chronic disease process.10
Table  1  Anti-neoplastics  with  single-agent  activity  (objective 
responses .10%) in platinum-resistant ovarian cancer (platinum-
free interval ,6 months) (listed in alphabetical order)
Altretamine
Bevacizumab
Docetaxel
epirubicin
etoposide (oral, every-21-day schedule)
Gemcitabine
ifosfamide
irinotecan
Paclitaxel (every-3-week or weekly schedule)
PLD
Pemetrexate
Tamoxifen
Topotecan
vinorelbine
Abbreviation: PLD, pegylated liposomal doxorubicin.Table 2 Trials involving single agent PLD in epithelial ovarian cancer (median PFS and overall survival)
Patient population PLD (Other agent)
Gordon et al17,20  Topotecan
Dose/schedule: 50 mg/m2 q-28 d Dose/schedule: 1.5 m/m2 q-21 d
Platinum-sensitive PFS: 28.9 weeks; OS: 108 weeks PFS: 23.3 weeks; OS: 71.1 weeks
Platinum-resistant PFS: 9.1 weeks; OS: 35.6 weeks PFS: 13.6 weeks; OS: 41.3 weeks
Ferrandina et al25 Gemcitabine
Platinum-resistant Dose/schedule: 40 mg/m2 q-28 d Dose/schedule: 1,000 mg/m2 day 1,8,15 q-28 d
PFS: 16 weeks; OS: 56 weeks PFS: 20 weeks; OS: 51 weeks
Mutch et al24 Gemcitabine
Dose/schedule: 50 mg/m2 q-28 d Dose/schedule: 1000  mg/m2 day 1,8 q-21 d
PFS: 3.1 months; OS: 13.5 months PFS: 3.6 months;  OS: 12.7 months
Abbreviations: OS, overall survival; PLD, pegylated liposomal doxorubicin; PFS, progression-free survival.
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Pegylated liposomal  
doxorubicin (PLD)
PLD is a formulation of the anti-neoplastic agent,   doxorubicin, 
encapsulated in a novel proprietary bilayer lipid sphere 
(“liposome”).11–14 This material is contained within and 
surrounded by a layer of polyethylene glycol. Pre-clinical 
evaluation revealed that the size (approximately 100 nm) 
and chemical structure of this liposome selectively interfered 
with its entry into the vasculature of normal organs (heart, 
gastrointestinal tract, lungs, brain).11–14
In contrast, there was evidence for preferential deposi-
tion and prolonged exposure within tumor deposits whose 
blood vessels are often morphologically quite abnormal, 
permitting leakage into the surrounding tissue. In addition, 
the polyethylene glycol covering decreased protein binding 
and appears to increase the time of circulation within the 
systemic compartment.
PLD in epithelial ovarian cancer: 
initial nonrandomized trial 
experience
Phase 1 trials of PLD confirmed the extended exposure 
within the systemic compartment to doxorubicin following 
a single administration, with the toxicity profile of the agent 
being similar to that observed, with continuous infusion of 
the parent anti-neoplastic.15 This experience emphasized the 
importance of drug delivery on an every-4-week   schedule, 
rather than a more frequent dosing strategy (eg, every 
3 weeks) commonly used in oncology, including the standard 
use of doxorubicin itself.
In these early and subsequent clinical trials, as well as 
in routine clinical use, the dose-limiting side effects of PLD 
have included stomatitis, mucositis, and the development of 
palmar-plantar erythrodysesthesia (PPE), or the “hand-foot 
syndrome”.16,17 Importantly, cardiac dysfunction appears to be 
far less of a concern with PLD than that associated with the par-
ent drug (doxorubicin), and both complete alopecia and serious 
bone marrow suppression are less commonly observed.
Nonrandomized Phase 2 trials of PLD in platinum-
  resistant ovarian cancer documented the biological activity 
of the agent in this clinical setting, with objective response 
rates of approximately 10%–20% being reported in several 
individual trials.16,18,19 It is relevant to note that this initial 
experience did not provide evidence that this agent was supe-
rior to alternative strategies that might have been employed 
in patients with platinum-resistant disease (eg, single agent 
topotecan), but in view of the limited therapeutic options in 
this difficult setting there was considerable interest to continue 
to explore the potential of this drug in ovarian cancer.
PLD in epithelial ovarian cancer: 
single-agent randomized Phase 3 
trial experience
The initial randomized trial examining PLD in epithe-
lial ovarian cancer compared this drug to single agent 
topotecan when employed as the initial “second-line” 
management strategy in women with both recurrent 
  (platinum-free interval .6 months) and resistant (platinum-
free   interval ,6 months) disease (Table 2).17,20 PLD was 
administered at a dose of 50 mg/m2 every 4 weeks and 
topotecan at 1.5 mg/m2 × 5 days every 3 weeks.
The results of this study, which have been widely dis-
cussed and debated in the literature, revealed no difference 
in either PFS or overall survival between the two strategies 
in the platinum-resistant setting. However, in patients with 
platinum-sensitive recurrent disease, there was a rather strik-
ing difference (in favor of the PLD arm) in overall survival, 
despite a far more modest improvement in PFS (in favor 
of PLD) (Table 2).17,20
While these results unequivocally support both the 
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appropriate interpretation of the trial results is difficult for 
several reasons. First, it has been noted that the comparison 
of single agent PLD to single agent topotecan in the recur-
rent ovarian cancer setting is actually rather irrelevant 
since the more rational comparison in this specific clinical 
circumstance would have been to a platinum drug (most 
likely   carboplatin), either as a single agent or as combina-
tion strategy (see discussion of carboplatin/PLD versus 
carboplatin/paclitaxel Phase 3 trial below). This is due to 
the known major activity of platinum agents in this specific 
patient population.1,9,21,22
Second, it has been suggested that one likely reason for 
the greater impact of PLD on overall survival, compared with 
PFS, was that more patients randomized to the PLD study 
arm were subsequently able to receive a platinum agent fol-
lowing completion of treatment on this protocol compared 
with women randomized to the far more bone-marrow sup-
pressing topotecan regimen (particularly when administered 
at the dose of 1.5 mg/m2 × 5 days). This interpretation, which 
remains entirely speculative as treatment employed follow-
ing removal from this study was not routinely collected as 
part of the study design, concludes that the PLD study arm 
“won” largely because more patients randomized to this 
regimen were able to receive the single most active drug in 
the malignancy, a platinum agent.
A final frequently cited interpretation of the study 
results is that more patients who completed treatment on 
the PLD regimen were able to “cross-over” to the active 
agent, topotecan, than were able to receive PLD (at that 
time an   “experimental drug” in this clinical setting) after 
they progressed on the topotecan study arm. Again, there 
are no data to directly support the validity of this claim as 
there is no evidence that the use of topotecan in this setting is 
either superior or even equivalent to a platinum agent, which 
would have been widely available to patients who completed 
  treatment on this protocol.
Several additional Phase 3 trials have been reported which 
directly compared single agent PLD to other single agents 
(paclitaxel, gemcitabine) in platinum-resistant (platinum-
free interval ,6 months) and “modestly” platinum-  sensitive 
(platinum-free interval 6–12 months) ovarian cancer 
(Table 2).23–25 While side-effect profiles of the agents often 
differed substantially, these studies essentially revealed the 
therapeutic equivalence for these agents in this difficult 
clinical setting.
Two additional points regarding the administration of 
single agent PLD in the second-line setting in women with 
epithelial ovarian cancer are worthy of highlighting before 
moving on to a discussion of evidence-based data   evaluating 
PLD-containing combination chemotherapy regimens in this 
malignancy.
In an earlier section of this review it was noted that 
ovarian cancer patients frequently receive multiple lines of 
therapy following initial documentation of disease recur-
rence or persistence. However, the majority of evidence-
based   trials in ovarian cancer (and other malignancies) that 
explore “second-line treatment” strategies are actually only 
examining the first of many regimens used in this population. 
It is reasonable to inquire whether there is evidence that the 
administration of PLD, or other biologically active agents in 
ovarian cancer improves either PFS or overall survival when 
delivered in the “third-line” (or later) setting.
In fact, in a somewhat controversial trial, patients with 
advanced ovarian cancer who had progressed after two prior 
treatment regimens were randomized to a “control arm” of 
either topotecan or PLD (based on which drug they had not 
received as “second-line” treatment) or an “experimental 
drug” (canfosfamide) (Table 3).26 As patients treated on the 
study control arm experienced a highly statistically signifi-
cant improvement in both PFS and overall survival compared 
with treatment with the “experimental regimen”, these data 
provide relevant (although admittedly indirect) evidence that 
treatment with a known biologically and clinically active anti-
neoplastic agent (including PLD and topotecan) as third-line 
treatment of ovarian cancer improves survival, compared 
with an inactive (or no) treatment in this setting.
The second point relates to the issue of the appropriate 
dose of single agent PLD to be used either as a “control arm” 
in ongoing and future clinical trials or in routine clinical 
practice. It was previously noted that the initial trials that 
examined the utility of PLD as second-line therapy of ovarian 
cancer employed a dose of 50 mg/m2 delivered on an every-
4-week schedule.17 This specific program was subsequently 
accepted for registration by drug regulatory authorities.
Unfortunately, the “50 mg/m2 every-28-day”dose and 
schedule of PLD results in a substantial incidence (approxi-
mately 20%–30%) of grade 3 “hand-foot-syndrome”.16,17 
Considerable clinical experience generated since the 
Table  3  PLD  or  topotecan  versus  canfosfamide  as  third-line 
chemotherapy of ovarian cancer26
Treatment Progression-free survival 
(median)
Overall survival 
(median)
PLD or topotecan 4.3 months 13.5 months
Canfosfamide 2.3 months 8.5 months
Note: P , 0.01.
Abbreviation: PLD, pegylated liposomal doxorubicin.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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  initial regulatory approval of PLD has revealed essentially 
  equivalent clinical activity with substantially less severe 
adverse events when this agent is administered at a dose of 
40 mg/m2 (rather than 50 mg/m2) on a 4-week schedule.19,27,28 
Further, existing evidence reveals the large majority of 
ovarian cancer patients treated with PLD in this palliative 
setting outside the confines of a clinical trial will be given 
the lower (40 mg/m2) dose.29 Based on these considerations, 
there appears to be little (if any) ethical justification today 
for the   administration of PLD at the initial regulatory 
  agency-approved dose level.
In addition, the results of two randomized Phase 3 trials 
provide additional strong, but indirect support for the conclu-
sion that the 40 mg/m2 dose level of PLD is therapeutically 
equivalent to the higher (and more toxic) dose approved for 
standard use in the second-line management of ovarian cancer 
(Table 2).24,25 In one study, single agent PLD, administered at 
a dose of 50 mg/m2 (every-4-week schedule) was compared 
with single agent gemcitabine,24 while in the second study, 
PLD was administered at a dose of 40 mg/m2 (every-4-week 
schedule) and again compared with gemcitabine.25 Both 
studies revealed essentially equivalent survival following 
treatment with single agent gemcitabine or either of the two 
PLD programs (40 or 50 mg/m2).
PLD in epithelial ovarian cancer: 
randomized trials of combination 
chemotherapy regimens
Several trials have explored the potential utility of PLD as 
a component of front-line treatment of advanced ovarian 
cancer. In a large multinational Phase 3 trial, one of four 
investigative study arms (compared with carboplatin plus 
paclitaxel) added PLD to the two-drug platinum/taxane 
combination.3 None of the investigational arms (including the 
addition of PLD) was shown to be superior to the standard 
carboplatin/paclitaxel regimen.3
In a recently reported and unfortunately underpowered 
Phase 3 trial, investigators substituted PLD for paclitaxel 
in the front-line chemotherapy program and compared this 
approach to the standard platinum/taxane regimen (Table 4).30 
While there were no statistically significant differences in 
either PFS or overall survival between the treatment arms, 
the trial was actually designed as a superiority (rather than a 
noninferiority) study. As a result, the appropriate interpreta-
tion is that the carboplatin/PLD arm failed to demonstrate 
superiority to standard carboplatin/paclitaxel, and not that 
the two study regimens were equivalent in efficacy.
In contrast to the difficult-to-interpret carboplatin/PLD 
front-line ovarian cancer study, a Phase 3 trial that directly 
compared carboplatin/PLD with carboplatin/paclitaxel as 
treatment of platinum-sensitive recurrent disease revealed 
rather surprising superiority for the PLD-containing program 
in PFS (median 11.3 months versus 9.3 months, P = 0.005) 
(Table 5).31 At the time of the report of this study, there was no 
difference in overall survival between the two study arms.
Another unexpected, currently largely unexplained, but 
potentially highly clinically relevant difference between 
the regimens in this “second-line” study was a statistically 
significantly reduced incidence in carboplatin-associated 
hypersensitivity reactions observed following treatment with 
the PLD-containing program, compared with the combination 
containing paclitaxel.30 The lower incidence of this clinically 
relevant side effect might have translated to a measurably 
greater percentage of patients who were able to receive a 
sufficient number of carboplatin treatment cycles to optimize 
their chances to experience benefit from the agent recognized 
to be the most important cytotoxic drug in the management 
of this malignancy.1,21,22
Of interest, a second much smaller randomized trial that 
compared single agent carboplatin to the combination of 
carboplatin plus PLD revealed a similar strikingly lower inci-
dence of carboplatin-associated hypersensitivity in patients 
randomized to the PLD-containing program (Table 5).32
Another Phase 3 randomized trial compared the com-
bination of PLD plus trabectedin versus PLD alone in both 
platinum-resistant and “moderately” platinum-sensitive 
  (platinum-free interval 6–12 months) recurrent ovarian 
cancer.33 As with the previously discussed Phase 3 trials 
in platinum-resistant ovarian cancer, there was no differ-
ence in PFS between the two study arms in this setting, 
but side effects were greater with the combination strategy 
(Table 6).
However, in the “moderately” platinum-sensitive popula-
tion the two-drug program was associated with a statistically 
significant improvement in PFS. Data on overall survival 
remained immature at the time of the initial study report. 
Unfortunately, the improvement in PFS, while potentially 
highly clinically relevant was accompanied by a greater 
Table 4 Carboplatin/PLD versus carboplatin/paclitaxel as initial 
chemotherapy of ovarian cancer30
Treatment Progression-free survival 
(median)a
Overall survival 
(median)b
Carboplatin/PLD 19.0 months 61.6 months
Carboplatin/paclitaxel 16.8 months 53.2 months
Notes: aP = 0.58; bP = 0.32.
Abbreviation: PLD, pegylated liposomal doxorubicin.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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incidence of serious toxicity. As a result, it is reasonable to 
inquire if this statistically significant improvement in time 
to disease progression actually translates into meaningful 
clinical benefit.
Further, similar to the previous discussion regarding 
interpretation of the recurrent disease data in the single 
agent PLD versus single agent topotecan clinical trial, it 
remains unknown how the two drug combination of PLD/
trabectadin would compare with single agent carboplatin, 
carboplatin plus PLD, or alternative carboplatin-based com-
bination chemotherapy strategies (eg, with gemcitabine) in 
this clinical setting.
PLD in epithelial ovarian cancer: 
future directions
Early phase trials have begun to explore the potential of 
adding PLD in combination with a variety of alternative 
drugs, including bevacizumab, and other “targeted agents” 
in management of epithelial ovarian cancer.
With the demonstrated superiority of carboplatin/PLD 
compared with carboplatin/paclitaxel in recurrent ovarian 
cancer,31 and the documented favorable impact on PFS associ-
ated with the addition of bevacizumab to front-line cytotoxic 
chemotherapy,5,6 it will be quite relevant to explore the addi-
tion of this anti-angiogenic agent with the   PLD-containing 
carboplatin combination in the second-line setting. Such a 
trial will be of particular interest if the pending results of a 
Phase 3 trial that compares the combination of carboplatin 
plus gemcitabine with carbopatin/gemcitabine plus bevaci-
zumab in recurrent ovarian cancer reveals the superiority of 
the three-drug approach.
As bevacizumab, and other anti-angiogenic agents, 
are known to potentially impair wound healing, it may be 
particularly relevant to make major efforts to avoid PLD-
induced mucous membrane or skin toxicity when this drug 
is combined with an anti-angiogenic. Data from the clinical 
trials experience will hopefully reveal the toxicity profile of 
such combinations, but caution is advised until such safety 
information is available.
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